Volker Heinemann

German Cancer Research Center — Germany

Medicine · Health Sciences

91h-index43.4kcitations1.2kworks2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(562), Pancreatic and Hepatic Oncology Research(258), Cancer Genomics and Diagnostics(235), Lung Cancer Treatments and Mutations(202), Gastric Cancer Management and Outcomes(165)

Publications1.2k total

Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic
Scientific Reports·2025· 1 citedOpen Access
Tumor-intrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches.
UNC Libraries·2025Open Access
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
Journal of Clinical Oncology·2025· 1 cited
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)
European Journal of Cancer·2025Open Access
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study
European Journal of Cancer·2025Open Access
Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for &lt;i&gt;RAS&lt;/i&gt; wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
page 1 of 62Next →

Frequent Co-authors

Sebastian Stintzing(9), Stefan Boeck(9), Markus Moehler(8), Frank Kullmann(8), Dominik Paul Modest(8), Andreas Jung(7), Eric Van Cutsem(6), Werner Scheithauer(6), Ludwig Fischer von Weikersthal(6), Dirk Arnold(5), Wolff Schmiegel(5), Christoph Kahl(5), Heinz‐Josef Lenz(5), Swantje Held(5), Thomas Kirchner(5), Rainer Porschen(5), Fortunato Ciardiello(4), Alfredo Falcone(4), Roberto Labianca(4), Jens Ricke(4)